AMRX Stock Analysis: Amneal Pharmaceuticals | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 5.403m USD | 12M Return: 104% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 35.9M
EPS Trend: 57.9%
Qual. Beats: 5
Rev. Trend: 99.0%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amneal Pharmaceuticals, Inc. (AMRX) is a global biopharmaceutical company that develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products across the United States, India, Ireland, and other international markets. Founded in 2002 and headquartered in Bridgewater, New Jersey, the company operates through three reporting segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment covers a broad range of dosage forms, including oral solids, sterile injectables, inhalation products, ophthalmics, transdermal patches, and biosimilars. The Specialty segment focuses on central nervous system and endocrine disorders, with key branded products such as Rytary, CREXONT, and Unithroid/ONGENTYS targeting Parkinsons disease and hypothyroidism. The AvKARE segment supplies pharmaceuticals, medical, and surgical products primarily to U.S. government agencies, including the Department of Defense and the Department of Veterans Affairs, and distributes products under the AvKARE and AvPAK labels.
The companys products reach patients and institutions through multiple channels, including wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, and government agencies. The pharmaceutical industry in which Amneal operates is characterized by long product development timelines, heavy regulatory oversight from agencies such as the U.S. Food and Drug Administration, and significant revenue exposure to patent expirations and generic competition, which is a central feature of Amneals Affordable Medicines segment.
- CREXONT Parkinsons drug launch drives Specialty segment revenue growth
- Generic drug pricing pressure weighs on Affordable Medicines margins
- AvKARE government contracts expand with DoD and VA demand
| Net Income: 122.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -1.16 > 1.0 |
| NWC/Revenue: 35.13% < 20% (prev 15.36%; Δ 19.77% < -1%) |
| CFO/TA 0.09 > 3% & CFO 303.9m > Net Income 122.4m |
| Net Debt (2.62b) to EBITDA (626.0m): 4.19 < 3 |
| Current Ratio: 2.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (328.9m) vs 12m ago 1.53% < -2% |
| Gross Margin: 38.66% > 18% (prev 36.69%; Δ 1.97% > 0.5%) |
| Asset Turnover: 88.22% > 50% (prev 84.10%; Δ 4.12% > 0%) |
| Interest Coverage Ratio: 1.77 > 6 (EBIT TTM 419.4m / Interest Expense TTM 237.5m) |
| A: 0.30 (Total Current Assets 1.80b - Total Current Liabilities 728.0m) / Total Assets 3.54b |
| B: -0.13 (Retained Earnings -472.7m / Total Assets 3.54b) |
| C: 0.12 (EBIT TTM 419.4m / Avg Total Assets 3.45b) |
| D: -0.01 (Book Value of Equity -45.4m / Total Liabilities 3.59b) |
| Altman-Z'' = 2.35 = BBB |
| DSRI: 1.05 (Receivables 902.7m/800.3m, Revenue 3.05b/2.83b) |
| GMI: 0.95 (GM 36.69% / 38.66%) |
| AQI: 0.84 (AQ_t 0.33 / AQ_t-1 0.40) |
| SGI: 1.08 (Revenue 3.05b / 2.83b) |
| TATA: -0.05 (NI 122.4m - CFO 303.9m) / TA 3.54b) |
| Beneish M = -3.08 (Cap -4..+1) = AA |
As of July 14, 2026, the stock is trading at USD 17.18 with a total of 2,859,137 shares traded. Over the past week, the price has changed by +1.54%, over one month by +5.79%, over three months by +33.90% and over the past year by +104.04%.
Current recommended Stop Loss: 16.00 (which is 6.9% or 2.2 ATR below the current price).
Amneal Pharmaceuticals has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy AMRX.
- StrongBuy: 1
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17.3 | 0.4% |
P/E Trailing = 45.7297
P/E Forward = 6.2972
P/S = 1.7739
P/B = 105.446
Revenue TTM = 3.05b USD
EBIT TTM = 419.4m USD
EBITDA TTM = 626.0m USD
Long Term Debt = 2.57b USD (from longTermDebt, last quarter)
Short Term Debt = 21.5m USD (from shortTermDebt, last quarter)
Debt = 2.82b USD (from shortLongTermDebtTotal, last quarter) + Leases 124.7m
Net Debt = 2.62b USD (calculated: Debt 2.82b - CCE 197.7m)
Enterprise Value = 8.03b USD (5.40b + Debt 2.82b - CCE 197.7m)
Interest Coverage Ratio = 1.77 (Ebit TTM 419.4m / Interest Expense TTM 237.5m)
EV/FCF = 39.10x (Enterprise Value 8.03b / FCF TTM 205.3m)
FCF Yield = 2.56% (FCF TTM 205.3m / Enterprise Value 8.03b)
FCF Margin = 6.74% (FCF TTM 205.3m / Revenue TTM 3.05b)
Net Margin = 4.02% (Net Income TTM 122.4m / Revenue TTM 3.05b)
Gross Margin = 38.66% ((Revenue TTM 3.05b - Cost of Revenue TTM 1.87b) / Revenue TTM)
Gross Margin QoQ = 44.31% (prev 36.50%)
Tobins Q-Ratio = 2.27 (Enterprise Value 8.03b / Total Assets 3.54b)
Interest Expense / Debt = 8.42% (Interest Expense 237.5m / Debt 2.82b)
Taxrate = 0.32% (584k / 181.9m)
NOPAT = 418.1m (EBIT 419.4m * (1 - 0.32%))
Current Ratio = 2.47 (Total Current Assets 1.80b / Total Current Liabilities 728.0m)
Debt / Equity = -62.13 (negative equity) (Debt 2.82b / totalStockholderEquity, last quarter -45.4m)
Debt / EBITDA = 4.19 (Net Debt 2.62b / EBITDA 626.0m)
Debt / FCF = 12.78 (Net Debt 2.62b / FCF TTM 205.3m)
Total Stockholder Equity = -84.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.54% (Net Income 122.4m / Total Assets 3.54b)
RoE = -144.7% (negative equity) (Net Income TTM 122.4m / Total Stockholder Equity -84.5m)
RoCE = 16.90% (EBIT 419.4m / Capital Employed (Equity -84.5m + L.T.Debt 2.57b))
RoIC = 15.59% (NOPAT 418.1m / Invested Capital 2.68b)
WACC = 8.30% (E(5.40b)/V(8.22b) * Re(8.25%) + D(2.82b)/V(8.22b) * Rd(8.42%) * (1-Tc(0.00)))
Discount Rate = 8.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 71.39 | Cagr: 14.26%
[DCF] Terminal Value 73.57% ; FCFF base≈216.8m ; Y1≈195.1m ; Y5≈166.0m
[DCF] Fair Price = 0.08 (EV 2.65b - Net Debt 2.62b = Equity 24.2m / Shares 319.3m; r=8.35% [WACC [floored]]; 5y FCF grow -12.32% → 2.50% )
[DCF] Fair Price = 0.08 (out of range, set to none)
EPS Correlation: 57.91 | EPS CAGR: 8.89% | SUE: 2.31 | # QB: 5
Revenue Correlation: 98.99 | Revenue CAGR: 11.13% | SUE: 0.24 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.23 | Chg30d=+0.22% | Revisions=+17% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.25 | Chg30d=-10.74% | Revisions=-50% | Analysts=5
EPS current Year (2026-12-31): EPS=0.99 | Chg30d=-0.98% | Revisions=+17% | GrowthEPS=+18.9% | GrowthRev=+2.9%
EPS next Year (2027-12-31): EPS=1.12 | Chg30d=-5.13% | Revisions=-50% | GrowthEPS=+13.8% | GrowthRev=+7.2%
[Analyst] Revisions Ratio: -27% (up=4, down=8)